Analysis of Serum IgG1 to Predict Progression and Therapeutic Effect in Patients with Multiple Myeloma

Table 8

Concentration of serum and urine light chains in patients with multiple myeloma before, during, and after treatment.

	Before treatment	During treatment	After treatment
Serum κ-LC (N = 74)	5102.57 ± 5198.35	1580.39 ± 1214.76	1169.37 ± 963.99^†
Serum λ-LC (N = 83)	3488.49 ± 3816.87	1099.27 ± 1070.41	761.48 ± 727.77^†
Urine κ-LC (N = 164)	145.71 ± 526.10	33.50 ± 206.75	15.82 ± 90.29
Urine λ-LC (N = 86)	656.10 ± 1413.11	130.30 ± 473.83	168.07 ± 648.79

Compared with the before treatment group, ; compared with the during treatment group, ^†.